$UroGen Pharma Ltd (URGN.US)$ New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC
$UroGen Pharma Ltd (URGN.US)$ New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC
$UroGen Pharma Ltd (URGN.US)$ UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
UroGen Pharma Ltd Stock Forum
New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC
New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC
Breakthrough Cancer Treatment JELMYTO Maintains 47.8-Month Response in Upper Tract Cancer Patients
Major Breakthrough: UroGen to Reveal 18-Month Cancer Treatment Data at Leading Urology Conference
UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102
UroGen's Major Pipeline Play: Revolutionary Cancer-Fighting Virus Acquisition Reshapes Growth Strategy
Breakthrough Bladder Cancer Treatment Achieves 83% Response Rate, FDA Decision Coming 2025
Clinical Trial Results: Cancer Drug Maintains Response for Nearly 4 Years, Surpassing Expectations
No comment yet